MedWatch

Investors worry about Lundbeck's future, analysts remain optimistic

A disappearing pipeline and the fear of potential overpriced acquisitions concern Lundbeck's investors. However, analysts maintain optimism.

Photo: Jens Dresling

Stock in Danish pharmaceutical company Lundbeck has been falling behind on Nasdaq Copenhagen for several years. Now, investors are concerned about the company's future.

Analysts, however, see the potential for double-digit growth of company equity, reports domestic business daily Børsen.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs